| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_866ffbc1d9d2840009e20d06c38b25ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_605954119f94d0e5c9b0a5909bd59922 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-432
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-16 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
1999-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c06b6c405dbb7abc4f2063d29876afe3 |
| publicationDate |
2000-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0027421-A2 |
| titleOfInvention |
LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE |
| abstract |
Topical application of soluble tumor necrosis factor receptor antagonist (sTNFRI) is shown to promote corneal transplant survival in a murine model of orthotopic allotransplantation, having a significant effect in prolonging graft survival. Furthermore, the promotion of graft survival is associated with a significant decrease in corneal inflammation. Therefore, sTNFRI and related antagonists to tumor necrosis factor-α activity can be used in a therapeutic composition for local prophylaxis and treatment of allograft rejection and a wide array of immunogenic inflammatory diseases of the eye. The composition comprises a therapeutically effective amount of a tumor necrosis factor-α antagonist in association with a pharmaceutically acceptable carrier vehicle for local application. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009052140-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011519949-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9138457-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9421241-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9447419-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7732421-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9730978-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8512706-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8945604-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3056218-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9580490-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015023972-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011520812-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2338511-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8551467-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8563028-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2815767-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2276496-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2276496-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9248161-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8506944-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9393285-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012106634-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8075893-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8541389-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2918269-A1 |
| priorityDate |
1998-11-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |